About our research group/lab
Nearly one out of every three people in the world has been infected by HBV, and one in twelve live with chronic HBV or HCV infection. HDV co-infects with HBV causing the most severe form of hepatitis. Epidemics of HEV occur periodically throughout the developing world. In recent years, HEV infections also become a rising health issue in western countries. The disease burden of HEV infection is specific for pregnant women and solid organ transplantation patients. We aim to develop accessible and affordable antiviral therapies, with focus on treating HEV infection.
HBV, HCV and HDV infections are the leading cause of liver cancer in the world. We investigate the mechanism how these hepatitis viruses interact with their hosts to understand the cause of liver carcinogenesis. Secondly, we study the stem cell population in the liver to understand how these cells contribute to cancer development and whether can be therapeutically targeted.
Wanlu Cao, PhD, email@example.com
Jiaye Liu, PhD candidate, firstname.lastname@example.org
Ling Wang, PhD candidate, email@example.com
Ruyi Zhang, PhD candidate, firstname.lastname@example.org
Yunlong Li, PhD candidate, email@example.com
Yang Li, PhD candidate, firstname.lastname@example.org
Zhijiang Miao, PhD candidate, email@example.com
Pengfei Li, PhD candidate, firstname.lastname@example.org